Scholarlink

Purpose <p>In 2016, the Society of Surgical Oncology and Choosing Wisely Campaign recommended against sentinel lymph node biopsy (SLNB) in women &gt; 70&#xa0;years with early-stage, hormone receptor-positive (ER/PR +) breast cancer, citing limited clinical benefit. Despite earlier evidence supporting de-implementation, SLNB rates remained high. We aimed to evaluate patient, tumor, facility, and unmeasured contextual factors associated with SLNB de-implementation using a national cohort.</p> Methods <p>We queried the National Cancer Database (NCDB) for women &gt; 70&#xa0;years diagnosed with early-stage ER/PR + and HER2-negative breast cancer between 2012 and 2019. A mixed effects logistic regression model assessed associations between SLNB non-utilization and patient, tumor, and facility-level characteristics. Interaction terms between year and facility breast surgery volume quartiles were included to examine trends over time. Reference Effect Measures (REM) were used to estimate the contribution of unmeasured contextual effects relative to measured covariates.</p> Results <p>Among eligible patients, SLNB use declined from 86.7% in 2012 to 81.0% in 2019. SLNB use was significantly associated with age, insurance, urbanization, distance to facility, education, income, tumor size, lymphovascular invasion, treatment type, facility region, program type, and surgical volume. Academic programs had the highest adjusted odds of SLNB non-utilization (AOR 1.62; 95%CI: 1.29–2.02), while facilities in the South had the lowest (AOR 0.53; 95%CI: 0.45–0.63). High-volume centers de-implemented more rapidly post-2016, with 24% higher odds of SLNB non-utilization per year. REM analysis identified patient age and unmeasured contextual effects as the predominant drivers of de-implementation.</p> Conclusion <p>SLNB use in older women is influenced by multi-level factors, with patient age and unmeasured contextual effects driving de-implementation—though progress remain slow and limited in the United States.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multi-level factors drive use of sentinel lymph node biopsy in older women with early-stage breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月22日

查看全文
  • Madeline B. Thomas,
  • Sumaya Abdul Ghaffar,
  • Haaris Kadri,
  • Christopher M. Quinn,
  • Laura D. Leonard,
  • Nicole M. Mott,
  • Salvador Rodriguez Franco,
  • Lia R. Assumpção,
  • Gretchen Ahrendt,
  • Sarah E. A. Tevis,
  • Nicole Christian,
  • Jodi Widner,
  • Alicia A. Heelan,
  • Ana L. Gleisner

摘要

Purpose

In 2016, the Society of Surgical Oncology and Choosing Wisely Campaign recommended against sentinel lymph node biopsy (SLNB) in women > 70 years with early-stage, hormone receptor-positive (ER/PR +) breast cancer, citing limited clinical benefit. Despite earlier evidence supporting de-implementation, SLNB rates remained high. We aimed to evaluate patient, tumor, facility, and unmeasured contextual factors associated with SLNB de-implementation using a national cohort.

Methods

We queried the National Cancer Database (NCDB) for women > 70 years diagnosed with early-stage ER/PR + and HER2-negative breast cancer between 2012 and 2019. A mixed effects logistic regression model assessed associations between SLNB non-utilization and patient, tumor, and facility-level characteristics. Interaction terms between year and facility breast surgery volume quartiles were included to examine trends over time. Reference Effect Measures (REM) were used to estimate the contribution of unmeasured contextual effects relative to measured covariates.

Results

Among eligible patients, SLNB use declined from 86.7% in 2012 to 81.0% in 2019. SLNB use was significantly associated with age, insurance, urbanization, distance to facility, education, income, tumor size, lymphovascular invasion, treatment type, facility region, program type, and surgical volume. Academic programs had the highest adjusted odds of SLNB non-utilization (AOR 1.62; 95%CI: 1.29–2.02), while facilities in the South had the lowest (AOR 0.53; 95%CI: 0.45–0.63). High-volume centers de-implemented more rapidly post-2016, with 24% higher odds of SLNB non-utilization per year. REM analysis identified patient age and unmeasured contextual effects as the predominant drivers of de-implementation.

Conclusion

SLNB use in older women is influenced by multi-level factors, with patient age and unmeasured contextual effects driving de-implementation—though progress remain slow and limited in the United States.